Lista de obras -

A wash step at collection of placental biopsies from preeclamptic pregnancies does not adversely affect levels of sFlt-1 or endoglin.

artículo científico publicado en 2015

Activating Transcription Factor 3 Is Reduced in Preeclamptic Placentas and Negatively Regulates sFlt-1 (Soluble fms-Like Tyrosine Kinase 1), Soluble Endoglin, and Proinflammatory Cytokines in Placenta.

artículo científico publicado en 2017

Assessing the sensitivity of placental growth factor and soluble fms-like tyrosine kinase 1 at 36 weeks' gestation to predict small-for-gestational-age infants or late-onset preeclampsia: a prospective nested case-control study

artículo científico publicado en 2018

Circulating GATA2 mRNA is decreased among women destined to develop preeclampsia and may be of endothelial origin

artículo científico publicado en 2019

Circulating adrenomedullin mRNA is decreased in women destined to develop term preeclampsia

scientific article published on 10 February 2019

Combining metformin and esomeprazole is additive in reducing sFlt-1 secretion and decreasing endothelial dysfunction - implications for treating preeclampsia.

artículo científico publicado en 2018

Disulfiram inhibits placental soluble FMS-like tyrosine kinase-1 and soluble endoglin secretion independent of the proteasome

scientific article published on 21 September 2018

Effect of sildenafil citrate on circulating levels of sFlt-1 in preeclampsia

artículo científico publicado en 2018

Effects of Pravastatin on Human Placenta, Endothelium, and Women With Severe Preeclampsia

artículo científico

Effects of simvastatin, rosuvastatin and pravastatin on soluble fms-like tyrosine kinase 1 (sFlt-1) and soluble endoglin (sENG) secretion from human umbilical vein endothelial cells, primary trophoblast cells and placenta

artículo científico publicado en 2016

Epidermal Growth Factor Rescues Endothelial Dysfunction in Primary Human Tissues In Vitro.

artículo científico publicado en 2016

Jumonji Domain Containing Protein 6 Is Decreased in Human Preeclamptic Placentas and Regulates sFLT-1 Splice Variant Production.

artículo científico publicado en 2016

Loss of Akt increases soluble endoglin release from endothelial cells but not placenta.

artículo científico publicado en 2016

Maternal plasma concentrations of the placental specific sFLT-1 variant, sFLT-1 e15a, in fetal growth restriction and preeclampsia.

artículo científico publicado en 2016

Metformin as a prevention and treatment for preeclampsia: effects on soluble fms-like tyrosine kinase 1 and soluble endoglin secretion and endothelial dysfunction.

artículo científico publicado en 2015

Nuclear factor of activated T-cells (NFAT) regulates soluble fms-like tyrosine kinase-1 secretion (sFlt-1) from human placenta.

artículo científico publicado en 2016

PSG7 and 9 (Pregnancy-Specific β-1 Glycoproteins 7 and 9): Novel Biomarkers for Preeclampsia

artículo científico publicado en 2022

Peptides do not prevent cleavage of endoglin to produce soluble endoglin.

artículo científico publicado en 2014

Placental-Specific sFLT-1 e15a Protein Is Increased in Preeclampsia, Antagonizes Vascular Endothelial Growth Factor Signaling, and Has Antiangiogenic Activity.

artículo científico publicado en 2015

Resveratrol inhibits release of soluble fms-like tyrosine kinase (sFlt-1) and soluble endoglin and improves vascular dysfunction - implications as a preeclampsia treatment.

artículo científico publicado en 2017

Screening circulating proteins to identify biomarkers of fetal macrosomia

scientific article published on 18 September 2019

Steroid sulfatase is increased in the placentas and whole blood of women with early-onset preeclampsia

artículo científico publicado en 2016

Sulfasalazine decreases soluble fms-like tyrosine kinase-1 secretion potentially via inhibition of upstream placental epidermal growth factor receptor signalling

scientific article published on 10 September 2019

YC-1 reduces placental sFlt-1 and soluble endoglin production and decreases endothelial dysfunction: A possible therapeutic for preeclampsia.

artículo científico publicado en 2015

Lista de obras de

A wash step at collection of placental biopsies from preeclamptic pregnancies does not adversely affect levels of sFlt-1 or endoglin.

Activating Transcription Factor 3 Is Reduced in Preeclamptic Placentas and Negatively Regulates sFlt-1 (Soluble fms-Like Tyrosine Kinase 1), Soluble Endoglin, and Proinflammatory Cytokines in Placenta.

Assessing the sensitivity of placental growth factor and soluble fms-like tyrosine kinase 1 at 36 weeks' gestation to predict small-for-gestational-age infants or late-onset preeclampsia: a prospective nested case-control study

Circulating GATA2 mRNA is decreased among women destined to develop preeclampsia and may be of endothelial origin

Circulating adrenomedullin mRNA is decreased in women destined to develop term preeclampsia

Combining metformin and esomeprazole is additive in reducing sFlt-1 secretion and decreasing endothelial dysfunction - implications for treating preeclampsia.

Disulfiram inhibits placental soluble FMS-like tyrosine kinase-1 and soluble endoglin secretion independent of the proteasome

Effect of sildenafil citrate on circulating levels of sFlt-1 in preeclampsia

Effects of Pravastatin on Human Placenta, Endothelium, and Women With Severe Preeclampsia

Effects of simvastatin, rosuvastatin and pravastatin on soluble fms-like tyrosine kinase 1 (sFlt-1) and soluble endoglin (sENG) secretion from human umbilical vein endothelial cells, primary trophoblast cells and placenta

Epidermal Growth Factor Rescues Endothelial Dysfunction in Primary Human Tissues In Vitro.

Jumonji Domain Containing Protein 6 Is Decreased in Human Preeclamptic Placentas and Regulates sFLT-1 Splice Variant Production.

Loss of Akt increases soluble endoglin release from endothelial cells but not placenta.

Maternal plasma concentrations of the placental specific sFLT-1 variant, sFLT-1 e15a, in fetal growth restriction and preeclampsia.

Metformin as a prevention and treatment for preeclampsia: effects on soluble fms-like tyrosine kinase 1 and soluble endoglin secretion and endothelial dysfunction.

Nuclear factor of activated T-cells (NFAT) regulates soluble fms-like tyrosine kinase-1 secretion (sFlt-1) from human placenta.

PSG7 and 9 (Pregnancy-Specific β-1 Glycoproteins 7 and 9): Novel Biomarkers for Preeclampsia

Peptides do not prevent cleavage of endoglin to produce soluble endoglin.

Placental-Specific sFLT-1 e15a Protein Is Increased in Preeclampsia, Antagonizes Vascular Endothelial Growth Factor Signaling, and Has Antiangiogenic Activity.

Resveratrol inhibits release of soluble fms-like tyrosine kinase (sFlt-1) and soluble endoglin and improves vascular dysfunction - implications as a preeclampsia treatment.

Screening circulating proteins to identify biomarkers of fetal macrosomia

Steroid sulfatase is increased in the placentas and whole blood of women with early-onset preeclampsia

Sulfasalazine decreases soluble fms-like tyrosine kinase-1 secretion potentially via inhibition of upstream placental epidermal growth factor receptor signalling

YC-1 reduces placental sFlt-1 and soluble endoglin production and decreases endothelial dysfunction: A possible therapeutic for preeclampsia.